Is imatinib mesylate a promising drug in systemic sclerosis?

Paul van Daele, Wim Dik, Bing Thio, PTW Hal, Jan van Laar, H (Herbert) Hooijkaas, P.M. van Hagen

Research output: Contribution to journalArticleAcademicpeer-review

49 Citations (Scopus)


A patient with therapy-resistant and progressive systemic sclerosis (SSc) with pulmonary involvement who was treated with imatinib mesylate is described herein. Prior to treatment. pulmonary fibroblasts obtained from the patient were cultured and incubated with imatinib mesylate. Preincubation of the fibroblasts for 1.6 hours with 2.5 mu g/ml imatinib mesylate efficiently abrogated platelet-derived growth factor BB-induced fibroblast proliferation. Furthermore, transforming growth factor PI-induced type I collagen gene transcription was blocked. During treatment, the patient's pulmonary involvement stabilized and her skin tightness improved. To our knowledge, this is the first report of a patient with therapy-refractory SSc responding to treatment with imatinib mesylate.
Original languageUndefined/Unknown
Pages (from-to)2549-2552
Number of pages4
JournalArthritis & Rheumatism
Issue number8
Publication statusPublished - 2008

Research programs

  • EMC MM-02-72-02
  • EMC MM-03-61-05-A

Cite this